Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Landos Biopharma, Inc. (LABP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/30/2023 |
8-K
| Appointed a new director|
Docs:
|
"LANDOS BIOPHARMA, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Landos Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware , does hereby certify as follows: FIRST: The name of the Company is Landos Biopharma, Inc. SECOND: The Company was originally formed as a corporation organized under the jurisdiction of the State of Delaware on January 6, 2017. THIRD: This Amended and Restated Certificate of Incorporation has been duly adopted and approved by the Board of Directors of the Company. The Certificate of Incorporation was last amended and restated by the Amended and Restated Certificate of Incorporation on February 8, 2021. FOURTH: This Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of ...",
"Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. NEW YORK, May 30, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. “Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos. “Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology.” Dr. Batycky brings with her over 25 years of global drug development experience in the biopharmaceutical industry, spanning from ..." |
|
| 05/25/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...|
Docs:
|
"CERTIFICATE OF AMENDMENTTOAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOF",
"Landos Biopharma Announces 1-for-10 Reverse Stock Split NEW YORK, May 25, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time today, May 25, 2023. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on May 26, 2023 under the existing trading symbol “LABP.” As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 515069201. The reverse stock split was previously approved by the stockholders of the Company at the annual meeting of sto..." |
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. “We continue to execute on a focused strategy for the NX-13 program to maximize value for our shareholders,” said Gregory Oakes, President and CEO of Landos. “Our NEXUS Phase 2 study of NX-13 in UC is designed to advance this important progra...",
"LP 0/4 4/11 4/10 3/11" |
|
| 04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
5
| Bassaganya-Riera Josep (10% Owner) has filed a Form 5 on Landos Biopharma, Inc. |
| 02/14/2023 |
SC 13G/A
| Bassaganya-Riera Josep reports a 14.2% stake in Landos Biopharma, Inc. |
| 01/13/2023 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 36.9% stake in Landos Biopharma, Inc. |
| 01/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/05/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks NEW YORK, November 10, 2022 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 and LABP-104,” said Gregory Oakes, President and CEO of Landos. “In August, we announced positive top-line results from our NX-13 Phase 1b trial, which showed a favorable safety and tolerability profile in ulcerative colitis p..." |
|
| 11/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/31/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/06/2022 |
SC 13D/A
| RTW INVESTMENTS, LP reports a 9.1% stake in Landos Biopharma, Inc. |
| 08/16/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/11/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/11/2022 |
8-K
| Investor presentation, Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
SC 13D/A
| Xontogeny, LLC reports a 7.7% stake in Landos Biopharma, Inc. |
| 08/09/2022 |
SC 13D/A
| PERCEPTIVE ADVISORS LLC reports a 36.9% stake in Landos Biopharma, Inc. |
| 08/03/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
|
|
|